Home > Boards > US Listed > Cannabis >

India Globalization Capital Inc. (IGC)

IGC RSS Feed
Add IGC Price Alert      Hide Sticky   Hide Intro
Moderator: Smilin_B
Search This Board: 
Last Post: 10/11/2019 3:32:18 AM - Followers: 194 - Board type: Free - Posts Today: 0

165 FOLLOWERS AS OF 10/14/2018 
iBox Update 10/14/2018 11:35 CrazyKar123
 

India Globalization Capital, Inc. (NYSE MKT: IGC) is a first mover in developing a portfolio of products using cannabis-based "combination therapies" for the treatment of pain and other conditions.

IGC's strategy is exciting and unique in that it is aiming to become a leader in the phytocannabinoid-based combination therapy specialty pharmaceutical sector. This first-mover advantage can potentially be formidable as it begins clinical trials and further builds its patent portfolio

IGC recently exited its legacy businesses and currently holds international investments in land and in a hotel project.

 

Investment Highlights

• Building a patented portfolio of phytocannabinoid-based pharmaceutical and nutraceutical products for one of the world's fastest growing industries
• Positioning for first-mover advantage by developing novel therapies, applying for patents, and acquiring technologies from related industries
• Strategic alliance with International Pharma Trials provides expertise in the FDA process and pharma-trials

 


Development Pipeline

Through cutting-edge research, IGC is developing a product portfolio of phytocannabinoid-based therapies for the treatment of a wide range of life altering or life threatening indications, including neuropathic and cancer pain, epilepsy, end of life supportive care, adjunctive supportive therapies of chronic neurological and oncological diagnosis.


Target Markets

Attitudes toward cannabis have transformed substantially across the United States. Support for cannabis legalization is rapidly outpacing opposition; 53 percent of Americans believe cannabis should be made legal, compared with 44 percent supporting illegality of cannabis. Within this burgeoning market, IGC has identified key areas to which it can apply its phytocannabinoid-based therapies to address unmet medical needs.

 

Pain

The treatment of pain is a great challenge for health care professionals as it can often debilitate individuals in ways that affect their day-to-day functioning, which significantly impacts the nation's productivity and economy. The national cost of health care due to pain ranges from $560 billion to $635 billion. In addition, the health care cost attributed to the abuse of prescription opioids, closely related to pain, is approximately $25 billion.

A major disadvantage of using currently available drug therapies to treat chronic severe pain is that these opioid based drugs may lead to side effects like hallucinations, constipation, sedation, nausea, respiratory depression, and dysphoria.

IGC-501

IGC has applied for a U.S patent based on a novel therapy, IGC-502 indicated for seizures, using cannabinoid extracts. The therapy is administered, using a variety of delivery technologies, for indications in mammals such as dogs and cats. The therapy may also be useful in humans.

IGC expects to conduct metabolic profiling and apply to the FDA for trials over the next few years.

 

Epilepsy

Approximately 50 million people worldwide are affected by epilepsy (Sanders, 2003), a condition attributed to multiple factors. In dogs and cats, seizures are often caused by abnormal brain activity. They can be subtle or cause violent convulsions. Some seizures only occur once, but repeated seizures require treatment to prevent larger areas of the brain from becoming affected.

IGC-502

IGC has applied for a U.S patent based on a novel therapy, IGC-502 indicated for seizures, using cannabinoid extracts. The therapy is administered, using a variety of delivery technologies, for indications in mammals such as dogs and cats. The therapy may also be useful in humans.

IGC expects to conduct metabolic profiling and apply to the FDA for trials over the next few years.

 

Eating Disorders

Cachexia is a condition that accompanies severe illness such as cancer and results in the weakness and wasting away of the body. Approximately 1.3 million people in the United States are experiencing cachexia associated with cancer, multiple sclerosis, Parkinson's disease, HIV/AIDS, and other progressive illnesses. Notably, cancer-induced anorexia/cachexia is responsible for about 20% of all cancer deaths.

IGC-504 and IGC-506

Indicated for a variety of eating disorders, including cachexia, IGC-504 and IGC 506 are unique combination therapies that, if proven out by clinical trials, are expected to treat medical refractory epilepsy and eating disorders respectively, with lower side effects than conventional mono therapies. IGC-506 is being developed for both human and veterinary use.

 


Industry Partnerships

IGC has established a strategic alliance with International Pharma Trials, whose doctors and researchers have expertise in disorders of the central and peripheral nervous system as well as expertise in the FDA process and pharma-trials.

The company continues to seek information exchanges with medical cannabis dispensaries, research scientists, doctors, medical and business professionals, and biotech companies working in the cannabinoid space.

Leveraging its business model and collaborative research, IGC can help commercialize products while finding innovative ways of helping patients benefit from cannabinoids.

 


Leadership


Ram Mukunda, President, CEO and Director

Ram Mukunda has served as IGC's executive chairman, chief executive officer, and president since the company's inception on April 29, 2005. From January 1990 to May 2004, Mukunda served as founder, chairman, and chief executive officer of Startec Global Communications, an international telecommunications carrier focused on providing voice over Internet protocol (VOIP) services to emerging economies. Startec was the first pure play international long distance carrier. Mukunda was responsible for organizing, structuring and integrating a number of companies owned by Startec. Under Mukunda's tenure at Startec, the company made an IPO of its equity securities in 1997 on NASDAQ. Prior to Startec, Mr. Mukunda served as Strategic Planning Advisor at Intelsat, a communications satellite services provider.

Mukunda serves as an emeritus member on the Board of Visitors at the University of Maryland, School of Engineering. From 2001 to 2003, he was a council member at Harvard's Kennedy School of Government, Belfer Center of Science and International Affairs.

Mukunda is the recipient of several awards including, the 2013 University of Maryland's International Alumnus of the Year award, the 2001 Distinguished Engineering Alumnus Award, the 1998 Ernst & Young, LLP's Entrepreneur of the Year Award. He holds a B.S. degree in Electrical Engineering, a B.S degree in Mathematics, and a M.S. in Engineering from the University of Maryland.

John Cherin, CFO, Treasurer, PAO

John Cherin is a retired senior executive with international experience in assisting young companies. He has provided insight to top management and Board of Directors on strategic analysis and improvement of operating procedures in financial reporting and operations. From 1966 to 1997, Cherin gained his experience as a senior partner at Arthur Andersen while managing practices aimed at businesses in the US and overseas. In addition he founded and managed Cherin Global Consulting in 1997-2005 and the Cherin Group LLC in 2004 to date. He also served as CFO for IGC in its formative stages for the purpose of raising capital to enable IGC's launch in the post startup phase.

Cherin is a retired CPA, a graduate of Northeastern University class of 1966 and in 1967 was the Silver Medal Recipient from the Massachusetts Society of CPAs.

Claudia Grimaldi, General Manager, Director of Cabaran Ultima

Claudia Grimaldi is the general manager and director of IGC's project development and managing company in Malaysia. Grimaldi is responsible for coordinating the staff in various countries and ensuring timely and accurate regulatory compliance and statutory reporting. Prior to assuming her current role in 2013, she spent three years managing the office of the CEO.

Prior to IGC, Grimaldi worked in human resources and psychotherapy. She graduated Summa Cum Laude from Javeriana University, a top five University in Colombia, with a Bachelor of Arts in Psychology. She holds an MBA in General Management, graduating with Highest Honors, from Meredith College. Grimaldi is a member of Delta Mu Delta International Honor Society. She is also fluent in both English and Spanish.

 


India Globalization Capital
PO BOX 60642
Potomac, MD 20859-0642
Phone: (301) 983-0998
www.IGCinc.us

NetworkNewsWire
1324 Lexington Ave.
Suite 117
New York, NY 10128
Phone: (212) 418-1217
www.NetworkNewsWire.com

 

NetworkNewsWire is a moderator of this board. Please see disclaimer on the NetworkNewsWire website: https://www.networknewswire.com/disclaimer/





 








https://www.otcmarkets.com/stock/IGC/security









 











 

IGC
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
IGC News: IGC Opens Marketing and Research Hub in Colombia 10/04/2019 07:00:00 AM
IGC News: IGC Announces IRB Approval of its IGC-AD1 for a Phase-2 study 09/19/2019 07:00:00 AM
IGC News: IGC Reports Financial Results for the Quarter Ended June 30, 2019 08/09/2019 07:00:00 AM
IGC News: Quarterly Report (10-q) 08/09/2019 06:09:28 AM
IGC News: IGC Reports Financial Results for the Fiscal Year Ended March 31, 2019 06/17/2019 07:00:00 AM
PostSubject
#7084  Sticky Note IGC News = Re-Listed on the NYSE by Smilin_B 02/23/19 05:17:39 AM
#8944   If Ram mukunda is going to be there, Smilin_B 10/11/19 03:32:18 AM
#8943   free presentation Oct 21 at the Shiprock Chapter Bruno2 10/10/19 03:13:42 AM
#8942   Where did IGC's $30,000,000 go off to? Bruno2 10/08/19 07:08:24 AM
#8941   Where did IGC's $30,000,000 go off to? Smilin_B 10/08/19 02:45:39 AM
#8940   press release Bruno2 10/04/19 08:48:12 AM
#8939   What is Ram Makunda doing with the remaining Smilin_B 09/20/19 02:02:00 AM
#8938   * * $IGC Video Chart 09-19-2019 * * ClayTrader 09/19/19 05:18:55 PM
#8937   Wow, HUGE! LexTrader 09/19/19 07:16:23 AM
#8936   News! GC Announces IRB Approval of its IGC-AD1 for paulatc 09/19/19 07:15:31 AM
#8935   not sure where you are getting your information paulatc 09/12/19 11:47:33 AM
#8934   I can tell you ONE place it went....The ChopNoamsky 09/09/19 07:25:31 PM
#8933   article (August 30, 2019) : "9 questions about Bruno2 09/08/19 09:28:22 AM
#8932   * * $IGC Video Chart 09-06-2019 * * ClayTrader 09/06/19 07:19:22 PM
#8931   article Drug Enforcement Administration (August 26, 2019) Bruno2 08/29/19 07:00:10 AM
#8930   Most entrepreneurs would kill to be on an Alexxdj1 08/15/19 08:33:07 AM
#8929   Yes, like me, you've been around for quite Smilin_B 08/14/19 06:55:52 PM
#8928   daily volume at 300k today, hard telling, I Alexxdj1 08/14/19 06:42:14 PM
#8927   I remember when CItron came in and went Alexxdj1 08/14/19 06:41:01 PM
#8926   Now of course we are Teeter tottering at Smilin_B 08/14/19 06:38:45 PM
#8925   They raised something close to 30 million dollars Smilin_B 08/14/19 06:37:47 PM
#8924   last report shows they still have cash on Alexxdj1 08/14/19 06:29:00 PM
#8923   Terrible whats becoming of IGC shares They raised $27,000,000 Smilin_B 08/12/19 03:16:02 PM
#8921   not stuck there anymore and earnings coming up. makingitnow 07/24/19 11:37:20 AM
#8920   It seems to be stuck in the $1.50 PePe Le Profit 07/15/19 02:29:48 PM
#8919   IGC performed a successful capital raise of $30,000,000 Smilin_B 07/15/19 03:35:16 AM
#8918   Im completely with you on this topic Smilin_B 07/12/19 02:54:34 AM
#8917   Multiple patents pending, pipeline and transparency are shown PePe Le Profit 07/12/19 12:26:28 AM
#8916   Nice website Smilin_B 07/12/19 12:13:30 AM
#8915   Have you been to the IGC website lately? http://www.igcpharma.com PePe Le Profit 07/11/19 10:02:55 PM
#8914   No, I'm saying dtea will do the same manofIsle 07/11/19 09:46:56 PM
#8913   I saw that, I missed the move to PePe Le Profit 07/11/19 09:36:24 PM
#8912   Wake up. Jsda and dtea are going to explode.... manofIsle 07/11/19 08:32:04 PM
#8911   It’s moving in the correct direction for that PePe Le Profit 07/11/19 02:49:41 PM
#8910   It is? IGC needs to DOUBLE from here in Smilin_B 07/11/19 02:45:05 PM
#8909   Looks like the action is picking up. PePe Le Profit 07/11/19 02:42:24 PM
#8908   Yes, very boring I sincerely never thought the commons Smilin_B 07/09/19 04:49:29 PM
#8907   I hold the warrants. Do not mind TonyJoe1957 07/09/19 08:00:31 AM
#8906   Quick, grab me another bucket! PePe Le Profit 07/08/19 03:18:35 PM
#8905   I only own the warrants and I do Smilin_B 07/05/19 07:03:30 PM
#8904   own both of these. when the CBD beverage makingitnow 07/05/19 05:13:31 PM
#8903   News: $IGC Penny Stocks to Watch: IGC and whytestocks 07/05/19 03:40:23 PM
#8902   Loading before the big day Monday grab me vplm4life 07/05/19 12:47:49 PM
#8901   It dipped just a little lower than my PePe Le Profit 07/05/19 10:27:22 AM
#8900   Short trading day but could be the day PePe Le Profit 07/03/19 12:01:47 PM
#8899   Enjoy these $1.40’s while they last! This could PePe Le Profit 07/03/19 11:55:52 AM
#8898   Yummy vplm4life 07/03/19 11:39:26 AM
#8897   Eye like what I see vplm4life 07/02/19 02:50:22 PM
#8896  Restored hello Femto Bruno2 07/02/19 04:17:54 AM
#8895   Agreed, he’s scratching his head searching for cents ddbl_our_buck 07/01/19 05:36:02 AM
#8894   Your post literally makes zero sense Smilin_B 06/28/19 06:20:56 PM
PostSubject